Aelin Therapeutics

Aelin Therapeutics' breakthrough Pept-in technology is a highly flexible and powerful platform that can be applied on any disease-related protein, representing a new paradigm in drug discovery and development to tackle diseases that are currently difficult to address with small molecule- and protein-based drugs. The technology is protected by a bro... ad and strong IP portfolio, trade secrets and knowhow. Active proteins fold into a three-dimensional structure during and after synthesis. However, some triggers, such as unfavorable environmental conditions or gene mutations, can disturb this folding process, resulting in the aggregation of proteins and thereby making them inactive. Aggregation prone regions (APR) promote this aggregation process and have been identified inside almost all proteins. The Pept-in technology has been discovered and developed based on the observation that the protein aggregation process can be induced in almost any protein by using a synthetic peptide that contains a target protein APR. Pept-ins can therefore functionally and selectively knock-out almost any protein, independent of structural or functional protein class, forming the basis of novel therapeutics against high-value undruggable targets to treat severe diseases with high unmet needs, including various types of cancer and infections.Read More